Bharat parenterals Limited reported its Q3FY26 financial results for the quarter ended December 31, 2025, showing a mixed performance with revenue challenges offset by a strong order book position. The pharmaceutical company's standalone operations faced headwinds primarily due to timing-related delays in institutional segment execution.

Standalone Financial Performance

The company's standalone revenue from operations declined significantly on a year-on-year basis, reflecting timing mismatches in institutional purchase order releases.

Sequentially, revenue remained relatively stable at ₹41.41 crore compared to ₹41.70 crore in Q2FY26. The company's gross profit margin normalized to 39.4% in Q3FY26, compared to 44.1% in the previous quarter and 43.3% in Q3FY25.

Order Book Disclosure

For the first time, Bharat Parenterals disclosed its order book position to enhance investor visibility and predictability.

Management expects this order book to provide substantial support for FY27 performance, particularly in the first half of the fiscal year.

Consolidated Results

On a consolidated basis, the company's performance reflected ongoing investments in subsidiaries and regulated market platforms.

Subsidiary Performance Updates

Innoxel Lifesciences

Innoxel Lifesciences achieved a significant regulatory milestone during the quarter with the successful completion of its EU GMP inspection.

Management maintains revenue guidance of ₹60-65 crore for the full year and expects the subsidiary to move into profit after tax profitability in FY27.

Varenyam Healthcare

Varenyam Healthcare continued its growth trajectory in the domestic branded formulations segment, focusing on anaesthesia and related therapies.

Management Outlook

Management provided guidance for the immediate quarter and expressed confidence in the medium-term outlook despite current challenges.

Q4FY26 Expectations:

• Standalone revenue expected to improve to approximately ₹50-55 crore
• Sequential recovery over Q2 and Q3 base levels

FY26 Full Year:

• Company does not expect to achieve earlier full-year guidance
• Shortfall attributed to timing shifts in institutional execution

FY27 Outlook:

• Expected to benefit significantly from deferred order book execution
• Strong start anticipated in H1FY27

The company emphasized that current revenue softness represents timing delays rather than structural demand issues, with institutional execution typically being uneven quarter-to-quarter. The disclosed order book of ₹303 crore provides substantial visibility for future revenue recognition and execution.

Bharat Parenterals Limited has announced a key senior management appointment, naming Mr. Keval Sanjaykumar Shah as Vice President - Operations effective January 01, 2026. The pharmaceutical company made this disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Appointment Details

The company has formally approved the appointment of Mr. Shah as a senior management personnel in the Vice President - Operations role. The appointment takes effect from January 01, 2026, with no specific term mentioned for the position.

Professional Background

Mr. Keval Shah brings substantial experience to his new role at Bharat Parenterals Limited. He holds an MBA degree from IMT Ghaziabad and has accumulated over 10 years of professional experience across multiple business functions.

His expertise spans several critical areas:

• Supply chain management
• Project management
• Team leadership
• Vendor management
• Business development

Leadership Profile

According to the company's disclosure, Mr. Shah is characterized as a young, dynamic, and results-driven business professional. His educational background and diverse experience have equipped him with a holistic and practical approach to both strategic decision-making and daily operations.

The company highlighted that his strong foundation in operations management and overall business administration, combined with his deep industry expertise and leadership capabilities, will be instrumental in advancing the organization's next phase of growth.

Regulatory Compliance

The appointment announcement was made in compliance with SEBI regulations, specifically under Regulation 30 read with Para A of Part A of Schedule III of the Listing Regulations. The disclosure also adheres to requirements outlined in SEBI Master Circular No SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

Company Secretary and Compliance Officer Sharmin Soni signed the regulatory filing, ensuring proper documentation and compliance with all applicable disclosure requirements. The appointment represents a strategic addition to the company's senior management team as it continues to strengthen its operational capabilities.